Sonia HernÃ¡ndez-DÃ-az

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10923175/publications.pdf

Version: 2024-02-01

100 papers	14,082 citations	38742 50 h-index	33894 99 g-index

102 all docs	102 docs citations	102 times ranked	13987 citing authors

#	Article	IF	Citations
1	A Structural Approach to Selection Bias. Epidemiology, 2004, 15, 615-625.	2.7	2,017
2	Causal Knowledge as a Prerequisite for Confounding Evaluation: An Application to Birth Defects Epidemiology. American Journal of Epidemiology, 2002, 155, 176-184.	3.4	1,107
3	Major Congenital Malformations after First-Trimester Exposure to ACE Inhibitors. New England Journal of Medicine, 2006, 354, 2443-2451.	27.0	1,100
4	Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn. New England Journal of Medicine, 2006, 354, 579-587.	27.0	821
5	Folic Acid Antagonists during Pregnancy and the Risk of Birth Defects. New England Journal of Medicine, 2000, 343, 1608-1614.	27.0	689
6	Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. American Journal of Obstetrics and Gynecology, 2011, 205, 51.e1-51.e8.	1.3	587
7	First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects. New England Journal of Medicine, 2007, 356, 2675-2683.	27.0	467
8	Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. Journal of Clinical Epidemiology, 2016, 79, 70-75.	5.0	449
9	Beyond the intention-to-treat in comparative effectiveness research. Clinical Trials, 2012, 9, 48-55.	1.6	348
10	Use of over-the-counter medications during pregnancy. American Journal of Obstetrics and Gynecology, 2005, 193, 771-777.	1.3	331
11	The Birth Weight "Paradox" Uncovered?. American Journal of Epidemiology, 2006, 164, 1115-1120.	3.4	303
12	Antidepressant Use in Pregnancy and the Risk of Cardiac Defects. New England Journal of Medicine, 2014, 370, 2397-2407.	27.0	296
13	Increase in Prescription Opioid Use During Pregnancy Among Medicaid-Enrolled Women. Obstetrics and Gynecology, 2014, 123, 997-1002.	2.4	291
14	Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA Psychiatry, 2016, 73, 938.	11.0	206
15	Mortality and Morbidity During Delivery Hospitalization Among Pregnant Women With Epilepsy in the United States. JAMA Neurology, 2015, 72, 981.	9.0	201
16	Antidepressant Use Late in Pregnancy and Risk of Persistent Pulmonary Hypertension of the Newborn. JAMA - Journal of the American Medical Association, 2015, 313, 2142.	7.4	198
17	Lithium Use in Pregnancy and the Risk of Cardiac Malformations. New England Journal of Medicine, 2017, 376, 2245-2254.	27.0	183
18	Patterns of Opioid Utilization in Pregnancy in a Large Cohort of Commercial Insurance Beneficiaries in the United States. Anesthesiology, 2014, 120, 1216-1224.	2.5	180

#	Article	IF	Citations
19	Statins and congenital malformations: cohort study. BMJ, The, 2015, 350, h1035-h1035.	6.0	172
20	Risk Factors for Persistent Pulmonary Hypertension of the Newborn. Pediatrics, 2007, 120, e272-e282.	2.1	163
21	Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. American Journal of Psychiatry, 2016, 173, 263-270.	7.2	162
22	Algorithms to estimate the beginning of pregnancy in administrative databases. Pharmacoepidemiology and Drug Safety, 2013, 22, 16-24.	1.9	154
23	Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. Pharmacoepidemiology and Drug Safety, 2013, 22, 1013-1018.	1.9	140
24	Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations. PLoS ONE, 2013, 8, e67405.	2.5	140
25	Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study. BMJ, The, 2015, 350, h2102-h2102.	6.0	140
26	National trends in antidepressant medication treatment among publicly insured pregnant women. General Hospital Psychiatry, 2013, 35, 265-271.	2.4	135
27	Incidence of serious upper gastrointestinal bleeding/perforation in the general population:. Journal of Clinical Epidemiology, 2002, 55, 157-163.	5.0	131
28	Use of topiramate in pregnancy and risk of oral clefts. American Journal of Obstetrics and Gynecology, 2012, 207, 405.e1-405.e7.	1.3	130
29	Randomized Trials Analyzed as Observational Studies. Annals of Internal Medicine, 2013, 159, 560-2.	3.9	125
30	Hypertension in Women of Reproductive Age in the United States: NHANES 1999-2008. PLoS ONE, 2012, 7, e36171.	2.5	104
31	The Most Commonly Dispensed Prescription Medications Among Pregnant Women Enrolled in the U.S. Medicaid Program. Obstetrics and Gynecology, 2015, 126, 465-473.	2.4	104
32	Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study. BMJ: British Medical Journal, 2017, 358, j3326.	2.3	104
33	Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ, The, 2013, 347, f4877-f4877.	6.0	94
34	Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations. JAMA Psychiatry, 2018, 75, 167.	11.0	93
35	Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. JAMA - Journal of the American Medical Association, 2018, 320, 2429.	7.4	90
36	Selective Serotonin Reuptake Inhibitor Use and Risk of Gestational Hypertension. American Journal of Psychiatry, 2009, 166, 320-328.	7.2	89

#	Article	IF	Citations
37	Late Pregnancy Î² Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. Pediatrics, 2016, 138, .	2.1	89
38	Validity of maternal and infant outcomes within nationwide Medicaid data. Pharmacoepidemiology and Drug Safety, 2014, 23, 646-655.	1.9	81
39	Use of realâ€world evidence from healthcare utilization data to evaluate drug safety during pregnancy. Pharmacoepidemiology and Drug Safety, 2019, 28, 906-922.	1.9	79
40	Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations. Obstetrics and Gynecology, 2017, 129, 174-184.	2.4	77
41	Risk of Gestational Hypertension in Relation to Folic Acid Supplementation during Pregnancy. American Journal of Epidemiology, 2002, 156, 806-812.	3.4	76
42	Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. Paediatric and Perinatal Epidemiology, 2009, 23, 18-28.	1.7	70
43	Antidepressant Use During Pregnancy and the Risk of Preterm Delivery and Fetal Growth Restriction. Journal of Clinical Psychopharmacology, 2009, 29, 555-560.	1.4	70
44	Î²-Blocker Use in Pregnancy and the Risk for Congenital Malformations. Annals of Internal Medicine, 2018, 169, 665.	3.9	65
45	Nonsteroidal Antiinflammatory Drugs in Late Pregnancy and Persistent Pulmonary Hypertension of the Newborn. Pediatrics, 2013, 131, 79-87.	2.1	64
46	Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study. American Journal of Obstetrics and Gynecology, 2015, 212, 337.e1-337.e14.	1.3	63
47	Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. American Journal of Psychiatry, 2018, 175, 564-574.	7.2	61
48	Use of Decongestants During Pregnancy and the Risk of Birth Defects. American Journal of Epidemiology, 2013, 178, 198-208.	3.4	59
49	Case-Crossover and Case-Time-Control Designs in Birth Defects Epidemiology. American Journal of Epidemiology, 2003, 158, 385-391.	3.4	57
50	Estimating Absolute Risks in the Presence of Nonadherence. Epidemiology, 2010, 21, 528-539.	2.7	57
51	Beginning and duration of pregnancy in automated health care databases: review of estimation methods and validation results. Pharmacoepidemiology and Drug Safety, 2015, 24, 335-342.	1.9	56
52	Positive predictive value of computerized records for major congenital malformations. Pharmacoepidemiology and Drug Safety, 2008, 17, 455-460.	1.9	51
53	Placental Complications Associated With Psychostimulant Use in Pregnancy. Obstetrics and Gynecology, 2017, 130, 1192-1201.	2.4	50
54	Good practices for the design, analysis, and interpretation of observational studies on birth spacing and perinatal health outcomes. Paediatric and Perinatal Epidemiology, 2019, 33, O15-O24.	1.7	49

#	Article	IF	Citations
55	Patterns of Outpatient Antihypertensive Medication Use During Pregnancy in a Medicaid Population. Hypertension, 2012, 60, 913-920.	2.7	48
56	Is there a direct effect of preâ€eclampsia on cerebral palsy not through preterm birth?. Paediatric and Perinatal Epidemiology, 2011, 25, 111-115.	1.7	46
57	From causal diagrams to birth weight-specific curves of infant mortality. European Journal of Epidemiology, 2008, 23, 163-166.	5.7	38
58	Antibiotics and oral contraceptive failure â€" a case-crossover study. Contraception, 2011, 83, 418-425.	1.5	37
59	Invited Commentary: Composite Outcomes as an Attempt to Escape From Selection Bias and Related Paradoxes. American Journal of Epidemiology, 2014, 179, 368-370.	3.4	34
60	Alteration of bioelectrically-controlled processes in the embryo: a teratogenic mechanism for anticonvulsants. Reproductive Toxicology, 2014, 47, 111-114.	2.9	33
61	Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data. Pharmacoepidemiology and Drug Safety, 2015, 24, 934-942.	1.9	33
62	Assessment of Antihistamine Use in Early Pregnancy and Birth Defects. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 666-674.e1.	3.8	32
63	Prenatal Treatment and Outcomes of Women With Opioid Use Disorder. Obstetrics and Gynecology, 2018, 132, 916-922.	2.4	31
64	Patients and investigators prefer measures of absolute risk in subgroups for pragmatic randomized trials. Journal of Clinical Epidemiology, 2018, 103, 10-21.	5.0	30
65	Antidepressant Use in Pregnancy and the Risk of Cardiac Defects. New England Journal of Medicine, 2014, 371, 1167-1169.	27.0	29
66	Risk of Major Malformations in Infants Following First-Trimester Exposure to Quetiapine. American Journal of Psychiatry, 2018, 175, 1225-1231.	7.2	28
67	Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study. BMJ, The, 2020, 368, m237.	6.0	28
68	Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLoS Medicine, 2020, 17, e1003322.	8.4	27
69	Quantification of selection bias in studies of risk factors for birth defects among livebirths. Paediatric and Perinatal Epidemiology, 2020, 34, 655-664.	1.7	27
70	Association of first trimester prescription opioid use with congenital malformations in the offspring: population based cohort study. BMJ, The, 2021, 372, n102.	6.0	26
71	Iatrogenic legacy from diethylstilbestrol exposure. Lancet, The, 2002, 359, 1081-1082.	13.7	24
72	Challenges of using primary care electronic medical records in the UK to study medications in pregnancy. Pharmacoepidemiology and Drug Safety, 2013, 22, 977-985.	1.9	24

#	Article	IF	Citations
73	Dietary Folate and the Risk of Nonfatal Myocardial Infarction. Epidemiology, 2002, 13, 700-706.	2.7	23
74	Association of Antipsychotic Drug Exposure in Pregnancy With Risk of Neurodevelopmental Disorders. JAMA Internal Medicine, 2022, 182, 522.	5.1	22
75	The Effect of Prenatal Treatments on Offspring Events in the Presence of Competing Events. Epidemiology, 2020, 31, 636-643.	2.7	20
76	First Trimester Exposure to Antiretroviral Therapy and Risk of Birth Defects. Pediatric Infectious Disease Journal, 2014, 33, 741-746.	2.0	19
77	Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study. BMJ, The, 2020, 369, m1494.	6.0	17
78	Methylenetetrahydrofolate Reductase Polymorphisms and the Risk of Gestational Hypertension. Epidemiology, 2005, 16, 628-634.	2.7	16
79	Prescription of medications during pregnancy: accidents, compromises, and uncertainties. Pharmacoepidemiology and Drug Safety, 2006, 15, 613-617.	1.9	15
80	Calcium Channel Blocker Exposure in Late Pregnancy and the Risk of Neonatal Seizures. Obstetrics and Gynecology, 2015, 126, 271-278.	2.4	15
81	Validity of claimsâ€based algorithms to identify neurodevelopmental disorders in children. Pharmacoepidemiology and Drug Safety, 2021, 30, 1635-1642.	1.9	14
82	Effects of analgesics on bone mineral density: A longitudinal analysis of the prospective SWAN cohort with threeâ€group matching weights. Pharmacoepidemiology and Drug Safety, 2018, 27, 182-190.	1.9	13
83	Zidovudine use in pregnancy and congenital malformations. Aids, 2017, 31, 1733-1743.	2.2	12
84	Can folic acid protect against congenital heart defects in down syndrome?. Birth Defects Research Part A: Clinical and Molecular Teratology, 2006, 76, 714-717.	1.6	10
85	Risk of Complications After a Peptic Ulcer Diagnosis: Effectiveness of Proton Pump Inhibitors. Digestive Diseases and Sciences, 2013, 58, 1653-1662.	2.3	10
86	Invited Commentary: Simple Models for a Complicated Reality. American Journal of Epidemiology, 2006, 164, 312-314.	3.4	8
87	Polypharmacy and comorbidities during pregnancy in a cohort of women with migraine. Cephalalgia, 2021, 41, 392-403.	3.9	8
88	Emulating a target trial of the comparative effectiveness of clomiphene citrate and letrozole for ovulation induction. Human Reproduction, 2022, 37, 793-805.	0.9	8
89	Effectiveness and safety of intrauterine insemination vs. assisted reproductive technology: emulating a target trial using an observational database of administrative claims. Fertility and Sterility, 2022, 117, 981-991.	1.0	8
90	Chronic prescription opioid use in pregnancy in the United States. Pharmacoepidemiology and Drug Safety, 2021, 30, 504-513.	1.9	7

#	Article	IF	Citations
91	International Registry of Coronavirus Exposure in Pregnancy (IRCEP) â€“ Cohort Description and Methodological Considerations. American Journal of Epidemiology, 2022, , .	3.4	7
92	Ischemic Placental Disease, Preterm Delivery, and Their Association With Opioid Use During Pregnancy. American Journal of Epidemiology, 2022, 191, 759-768.	3.4	6
93	The Patterns of Use of Medications for Inflammatory Bowel Disease During Pregnancy in the US and Sweden Are Changing. Inflammatory Bowel Diseases, 2021, 27, 1427-1434.	1.9	6
94	Name of the Bias and Sex of the Angels. Epidemiology, 2011, 22, 232-233.	2.7	5
95	The Impact of Technology on the Diagnosis of Congenital Malformations. American Journal of Epidemiology, 2019, 188, 1892-1901.	3.4	5
96	Using nationally representative survey data for external adjustment of unmeasured confounders: An example using the NHANES data. Pharmacoepidemiology and Drug Safety, 2020, 29, 1151-1158.	1.9	4
97	In utero opioid exposure and risk of infections in childhood: A multinational Nordic cohort study. Pharmacoepidemiology and Drug Safety, 2020, 29, 1596-1604.	1.9	4
98	Trajectories of Prescription Opioid Utilization During Pregnancy Among Prepregnancy Chronic Users and Risk of Neonatal Opioid Withdrawal Syndrome. American Journal of Epidemiology, 2022, 191, 208-219.	3.4	4
99	Toh et al. Respond to "Compromise or Compromising?". American Journal of Epidemiology, 2007, 167, 644-645.	3.4	1
100	Reply. Obstetrics and Gynecology, 2014, 124, 638.	2.4	0